TB Research

Lipid nanoparticles biocompatibility and cellular uptake in a 3D human lung model

Magalhães J, Pinheiro M, Drasler B, Septiadi D, Petri-Fink A, Santos SG, Rothen-Rutishauser B, Reis S

Nanomedicine (London, England) · 2019-12

Abstract

Aim: Design nanostructured lipid carriers (NLC) to facilitate drug delivery to tuberculosis-infected areas, exploiting macrophage mannose receptors and assess their uptake in a 3D human lung model. Materials & methods: NLCs and mannosylated-NLCs were synthetized and characterized. Their uptake and biocompatibility were tested in a 3D human lung model. Results: The formulations have appropriate size (170-202 nm) and morphology for lung deposition. Cell membrane integrity was maintained and no significant pro-inflammatory cytokine (IL-1β, IL-8 and TNF-α) secretion or morphological changes were observed 24 h post nanoparticles exposure. NLCs and mannosylated NLCs were distributed in the apical side of the lung tissue, both in macrophages and in epithelial cells. Conclusion: NLCs are biocompatible carriers and can be used for pulmonary drug delivery.

MeSH terms

  • Lung
  • Cell Membrane
  • Macrophages
  • Humans
  • Tuberculosis
  • Lipids
  • Tumor Necrosis Factor-alpha
  • Lectins, C-Type
  • Mannose-Binding Lectins
  • Receptors, Cell Surface
  • Interleukin-8
  • Drug Delivery Systems
  • Nanostructures
  • Interleukin-1beta
  • Mannose Receptor